Navigation Links
Aethlon Medical Initiates Swine Flu Testing Program
Date:8/10/2009

SAN DIEGO, Aug. 10 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) today disclosed that researchers have initiated testing of its Hemopurifier(R) as a candidate treatment against the H1N1 Swine Flu Virus. The Hemopurifier(R) is the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The device has been designed to enhance the benefit of antiviral drug regimens, and it provides a therapeutic option against infectious viruses not addressed by drug and vaccine therapies.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)

The studies, which are testing the effectiveness of the Hemopurifier(R) to capture the H1N1 virus, are being conducted at laboratories approved by the United States Department of Health and Human Services to house and conduct research on pandemic strains of H1N1 virus. The Hemopurifier(R) has previously proven effective in capturing the reconstructed Spanish flu of 1918 virus (1918rv) and the H5N1 avian influenza virus (Bird Flu). The Hemopurifier(R) represents a promising strategy to clear infectious H1N1 swine flu from the bloodstream as the device selectively captures influenza viruses by hemagglutinin (HA) and neuraminidase (NA) glycoproteins that coat the virus, even when influenza mutates to be resistant against drug and vaccine therapies.

The World Health Organization (WHO) now projects that two billion people, or one third of the world's population, will become infected by the virus before the end of the pandemic. Last week, WHO also reported that 1,154 swine flu victims have died since the virus emerged in April, including 338 deaths reported in the prior week alone. Additionally, six patients have recently been identified with viral strains resistant to treatment with Tamiflu, the stockpiled antiviral treatment for pandemic forms of influenza.

"Beyond surging death tolls and reports of drug resistance, the potential for the swine flu virus to mutate into a virulent and lethal form seems increasingly possible over the course of the two billion infections projected by WHO," stated Aethlon Chairman and CEO, Jim Joyce. "While our primary focus remains the treatment of Hepatitis-C virus (HCV), it is now appropriate and important that we take advantage of the opportunity to validate the capability of our Hemopurifier(R) against infectious H1N1 Swine flu virus," concluded Joyce.

Since the beginning of 2009, the Hemopurifier(R) has been demonstrated safe and effective in reducing patient viral load in both Hepatitis-C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections. As a result, Aethlon believes the Hemopurifier(R) is the first therapeutic candidate to demonstrate viral reduction benefit against two different viral species in human studies. Such data further reinforces the position of the Hemopurifier(R) as a leading broad-spectrum countermeasure against drug and vaccine resistant viruses. Should H1N1 Swine Flu evolve to be highly virulent and resistant to treatment stockpiles, the Hemopurifier(R) is positioned to become a first-line treatment countermeasure to strengthen the clinical benefit of both established and candidate drug treatments.

About Aethlon Medical

Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier(R) represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier(R) seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.

    Contacts:

    Jon Cunningham
    RedChip Companies Inc.
    (407) 644-4256
    (407) 491-4498 -cell
    www.redchip.com
    Dave@redchip.com

    Jim Joyce
    Chairman, CEO
    858.459.7800 x301
    jj@aethlonmedical.com


    Jim Frakes
    Senior VP Finance
    858.459.7800 x300
    jfrakes@aethlonmedical.com

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier(R) to reduce viral loads and other disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Aethlon Medical Announces CEO Interview and Corporate Presentation Available Online
2. Aethlon Medical Announces Engagement of RedChip Companies to Initiate Investor and Media Relations Programs
3. Aethlon Medical Confirms Hemopurifier(R) Is a Treatment Candidate Against Swine Flu Virus
4. Aethlon Medical Discloses New HIV/AIDS Treatment Data
5. Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
6. Aethlon Medical Announces U.S. Army Agreement
7. MSU engineering team designs innovative medical device
8. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
9. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
10. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
11. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... Center for Autism and Related Disorders (CARD) Portland today announced ... disorder (ASD) and other developmental disabilities. The group, which is being launched with the ... the opportunity to share stories and advice, seek help, and continue their education on ...
(Date:12/2/2016)... ... 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces the cover of ... was inspired to practice medicine at an early age by his father, who was ... diagnoses and prescribing medicine,” he states. “It is about building relationships with people; relationships ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... two ostomy patients, standing as living proof that attitude and determination can combine ... and issues that spike around the holidays. This campaign will offer patients a ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of American teens report losing ... report speaking with their child about sex related topics, less than 60 percent spoke ... proud to announce the launch of its second edition of the “Sexual Wellness” campaign, ...
(Date:12/2/2016)... ... 02, 2016 , ... CloudLIMS.com, a class-leading provider of Laboratory ... CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep track of their ... version is a faster and a more efficient product, allowing batch processing of ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... -- UCB is pleased to announce that 12 scientific abstracts have ... American Epilepsy Society (AES) Annual Meeting, which takes place ... USA. 1-12 Data being presented include ... ® (lacosamide) CV and BRIVIACT ® (brivaracetam) CV. ... state of the union of epilepsy care and antiepileptic drugs ...
(Date:12/2/2016)... -- Allergan plc (NYSE: AGN ), a leading ... announced Accelerated Share Repurchase (ASR) Program. Logo - ... , ... announced, the Company entered into a variable tenor ASR arrangement ... $10 billion of its ordinary shares. Approximately 40.5 million shares ...
(Date:11/30/2016)... , Nov 30, 2016 Research and ... Intracranial Pressure Monitoring Devices 2017 - MedCore" report to their offering. ... , , ... brain and the skull. In healthy individuals, it is circulated though the ... are cases where the amount of CSF surrounding the brain changes significantly. ...
Breaking Medicine Technology: